New hope for rare joint disease: arthritis drug tocilizumab tested in CPPD
NCT ID NCT07254637
First seen Dec 08, 2025 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This study tests whether tocilizumab, an anti-inflammatory drug already used for rheumatoid arthritis, can reduce joint pain and improve quality of life in people with chronic inflammatory calcium pyrophosphate deposition disease (CPPD) that hasn't improved with standard treatments. Eighty adults will receive monthly infusions of tocilizumab or a placebo for three months. The main goal is to see if pain decreases after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CALCIUM PYROPHOSPHATE DEPOSITION DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Dijon
Dijon, 21000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Nantes
Nantes, 44000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Rennes
Rennes, 35200, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Saint-Étienne
Saint-Etienne, 42100, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Hospitalier Sud-Francilien
Corbeil-Essonnes, Paris, 91100, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Groupe Hospitalier Intercommunal Le Raincy-Montfermeil
Paris, 93370, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Groupe Hospitalier de l'Institut Catholique de Lille
Lomme, Lille, 59462, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Bichat Claude-Bernard
Paris, 75018, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Le Kremlin Bicêtre
Paris, 94270, France
-
Hôpital Tenon
Paris, 75020, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital de la Croix Saint-Simon
Paris, 75020, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lariboisière hospital
Paris, Paris Paris, 75010, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab (a drug that blocks inflammation, given as an IV infusion)
What this could lead to
If it works, this could offer a new treatment option for people with chronic inflammatory CPPD who have not responded to standard therapies.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 80 participants. The drug may not prove effective, and side effects from tocilizumab (such as infections) are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.